151838-62-9Relevant articles and documents
Discovery of small-molecule nonpeptide antagonists of nociceptin/orphanin FQ receptor: The studies of design, synthesis, and structure-Activity relationships for (4-Arylpiperidine substituted-methyl)-[bicyclic (hetero)cycloalkanobenzene] derivatives
Hayashi, Shigeo,Ohashi, Katsuyo,Mihara, Sachiko,Nakata, Eriko,Emoto, Chie,Ohta, Atsuko
, p. 345 - 364 (2016/04/19)
Nociceptin/orphanin FQ (N/OFQ) and N/OFQ peptide (NOP) receptor are expressed and distributed in various regions such as central nervous system (CNS), peripheral nervous system, immune system, and peripheral tissues. N/OFQ and NOP receptor have important
Collection of traceable compounds and uses thereof
-
, (2010/07/06)
The use of a collection of compounds of general formula (I), wherein: n is 0 or 1; p represents an integer between 1 and 6; r represents an integer between 1 and 12; R1 and R′1 represent in particular a hydrogen atom; R2 represents an amino acid side chain or an amino acid derivative; R3 represents a group derived from a carboxylic acid, bearing a basic entity; R4 represents in particular an alkyl group containing 1 to 10 carbon atoms; and A represents a hydrogen atom, a protecting group or a tracing group, in particular a fluorophor, a coloring agent or a quencher, for determining, through binding studies, ligands of receptors whose ligand is unknown or whose ligand useful for carrying out specific affinity binding assays is unknown.
TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF
-
Page/Page column 26, (2010/11/28)
The present invention provide a tetrahydroisoquinoline compound having a superior ACAT-inhibitory activity and/or anti-oxidation action, particularly, novel compound represented by the formula (I) (wherein each symbol is as described in the specification) and a pharmaceutically acceptable salt thereof.